Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Risankizumab in Moderate to Severe Hidradenitis Suppurativa
jRCT2080224861Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of risankizumab in hidradenitis suppurativa (HS) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16. Started Sep 2019; status: completed.
02
Drugs
risankizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2080224861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224861.